CliffBio
biologic

Activase

alteplase

Loss of exclusivityNovember 1999projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameActivase
Active ingredientalteplase
Strength50MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 1987
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Activase patent cliff — loss of exclusivity November 1999 | CliffBio